Initially, the company will get around $17m over 18 months from BARDA to ramp up the development of HemaMax.
Additional financing over the next 3.5 years is available in milestone-based options to be exercised by BARDA, potentially bringing the total value of the award to approximately $273m.
Neumedicines president and CEO Lena Basile said they have been working with BARDA to further the development of HemaMax as a radiation countermeasure since 2008, and are now pleased to extend this partnership under this current contract to fund the advanced development of HemaMax.
"With this funding, Neumedicines is positioned to accelerate the nonclinical efficacy and human safety development of HemaMax towards FDA approval under the Animal Rule," Basile said.